Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.72 |
| ▸ | NPC1 | O15118 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.69 |
| ▸ | AXL | P30530 | 1/20 | 0.61 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.61 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13480645 | 1.00 | KDM4E (1.00) | KDM4EARKMT2ARAB9ACYP19A1 | |
| SCHEMBL12601865 | 0.96 | KDM4E (0.93) | KDM4EARKMT2ARAB9ACYP19A1 | |
| SCHEMBL2781370 | 0.92 | KDM4E (0.85) | KDM4EARKMT2ARAB9ACYP19A1 | |
| SCHEMBL11213828 | 0.90 | SREBF2 (0.82) | KDM4EARKMT2ARAB9ACYP19A1 | |
| SCHEMBL11215130 | 0.90 | SREBF2 (0.82) | KDM4EARKMT2ARAB9ACYP19A1 | |
| SCHEMBL11212983 | 0.90 | SREBF2 (0.82) | KDM4EARKMT2ARAB9ACYP19A1 | |
| SCHEMBL11464717 | 0.88 | SREBF2 (0.79) | KDM4EARKMT2ARAB9ACYP19A1 | |
| SCHEMBL17014786 | 0.84 | CYP19A1 (1.00) | KDM4EARKMT2ARAB9ACYP19A1 | |
| SCHEMBL7495850 | 0.84 | RAB9A (1.00) | KDM4EARKMT2ARAB9ACYP19A1 | |
| SCHEMBL30128572 | 0.84 | CYP19A1 (1.00) | KDM4EARKMT2ARAB9ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014172639-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2014-10-23 | — | — | WO | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| CN-102015686-B | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2014-07-02 | — | — | CN | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| CN-102015686-A | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | KDM4E 3041/4885AR 3762/4885KMT2A 2016/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | KDM4E 2526/4885AR 3602/4885KMT2A 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.